Shares of psychedelic drug developers surged following an executive order from Donald Trump that expands incentives for certain therapies. The order directs the FDA to grant Commissioner’s National Priority Vouchers (CNPVs) to “appropriate” psychedelic drugs that have already secured Breakthrough Therapy designation and meet the voucher program's criteria. The announcement marks a significant policy shift for a class of compounds often associated with mental health treatment.
The CNPV program, created by the FDA, is designed to accelerate the development and review of drugs that address unmet medical needs. Under the order, qualifying psychedelic compounds will receive priority review vouchers that can expedite regulatory decisions. Sources indicate that several companies with ongoing mid- to late-stage trials for conditions like PTSD and depression could be the first to benefit from this pathway.
While no specific drugs or companies were named in the executive order, analysts expect candidates such as MDMA-assisted therapy and psilocybin-based treatments to be among the eligible assets. The FDA’s Breakthrough Therapy designation has previously been granted to several psychedelic programs, including those from MAPS Public Benefit Corporation and Compass Pathways. The policy change effectively creates a faster route to market for these therapies.
Investor enthusiasm was immediate. Share prices for firms like Cybin, MindMed, and Atai Life Sciences rose between 8% and 15% in the hours following the announcement. The order signals a potential regulatory thaw for psychedelic medicine, which has historically faced skepticism from lawmakers. However, the broader market for these treatments remains experimental, with no FDA-approved psychedelics currently available outside of limited clinical settings.
Critics caution that the voucher program does not guarantee clinical efficacy or safety data sufficient for full approval. The executive order is a political directive, not a change in FDA statutory authority, meaning the agency must still apply its traditional scientific standards. Patient advocacy groups warn that accelerated pathways must not compromise rigorous safety review, especially given the potent nature of psychedelic compounds. The long-term impact on drug pricing and access also remains unclear.